DERM as of Nov 4 · 04:04 ET
DERMNasdaqPharmaceutical Preparations

Journey Medical Corp · Brief

Next report

7 days

Nov 11 · after closeest.Q3 FY26

Expected move

No implied move.

Implied vs realized

8 reportsHistory
0 of 4≥ implied
avg implied
±63.4%
avg realized
±17.8%
Feb 5 '25—▼−5.30%—
Mar 26 '25—▼−3.58%—
May 14 '25—▲+18.93%—
Aug 12 '25—▼−15.11%—
Q3 FY25±56.7%▼−15.31%×0.27
Q1 FY26±87.6%▼−30.01%×0.34
May 13 '26±25.1%▲+22.35%×0.89
Q2 FY26±84.3%▲+3.42%×0.04
quarterimplied−90%0+90%realized×
Q2 FY26±84.3%▲+3.42%×0.04
May '26±25.1%▲+22.35%×0.89
Q1 FY26±87.6%▼−30.01%×0.34
Q3 FY25±56.7%▼−15.31%×0.27
Aug '25—▼−15.11%—
May '25—▲+18.93%—
2 older reports
Mar '25—▼−3.58%—
Feb '25—▼−5.30%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 11 report · est.

Bull2 of 3

7disclosed supplier and customer ties in SEC filingsSEC filings
71managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

11 of 22of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
14managers whose positions together make up four fifths of the reported value13F · Jun 30 '26
AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

DERM report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 28impliedImplied move: ±83.0% into Nov 11 earnings (Oct 28 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.